Navigation Links
Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Date:3/10/2009

CAMBRIDGE, Mass., March 10 /PRNewswire/ -- Tolerx, Inc., today announced that DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), the Phase 3 trial of otelixizumab, an investigational novel targeted immunotherapeutic, has begun enrollment of new onset autoimmune type 1 diabetes patients in Europe. In DEFEND, preserving beta cell function subsequent to the administration of otelixizumab is the primary outcome that is being evaluated. This outcome will be assessed by measuring C-peptide levels (a surrogate of endogenous insulin secretion) and by measuring reductions in the amount of injected insulin used to maintain excellent glycemic control.

DEFEND continues to actively recruit subjects in the United States, Canada, Sweden, Finland, Germany, Italy, and the UK. Tolerx anticipates that enrollment will soon commence at clinical sites in Spain and Denmark.

"Our participation in DEFEND reflects our research priorities to support the development of innovative immune intervention for type 1 diabetes patients. We have begun dosing otelixizumab in DEFEND and are excited about its potential to be an effective treatment option for type 1 diabetics," stated Dr. Paolo Pozzilli, Professor University Campus Bio-Medico, Rome Italy.

"We are pleased that an increasing number of excellent clinical researchers in Europe and North America have started DEFEND at their sites and look forward to their continued participation in this important effort. We believe that a single short course of otelixizumab may have the potential to preserve residual beta cell function and offer people with autoimmune type 1 diabetes improved disease control" said Dr. Louis Vaickus, Chief Medical Officer of Tolerx. He continued "We are seeking in DEFEND to conclusively demonstrate this understanding."

About the DEFEND Study

DEFEND is a
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
2. Laureate Announces Manufacturing Agreement with Tolerx
3. ATS Medical Expands Open Pivot Heart Valve Offerings
4. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
5. BioLife Solutions Expands Scientific Advisory Board
6. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Pharsight Expands Strategic Consulting Services Team
9. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
10. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
11. AQUISS Expands Into Significant New Territory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... (PRWEB) August 23, 2014 ... Partners LLC announced today that Janet B. Arrowsmith, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:8/22/2014)... This is a professional and ... Papain industry in Global and China. The report ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ... the international and Chinese situation is also offered. ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) ... of Appeals for the D.C. Circuit challenging the FAA’s Interpretation ... Federal Register on June 25, 2014. , The AMA ... text and intent of the FAA Modernization and Reform Act ... on any new rules or regulations regarding model aircraft that ...
(Date:8/22/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results for ... complete 2014 second quarter financial statements and MD&A have been filed on ... 30, , Six-months ended June 30, ( in CDN$,000 except ... , 2014 , 2013 Revenue , 2,459 ... profit , 56 , 1,485 , 385 ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... today that,Anthony DiTonno, President and Chief Executive Officer, ... Healthcare Unplugged Conference in New,York City on Tuesday, ... Financial Officer, will be available to respond to ...
... BETHESDA, Md., Sept. 2 Micromet, Inc.,(Nasdaq: ... company,developing novel, proprietary antibodies for the treatment of ... of,Barclay A. Phillips as Senior Vice President and ... member of the Company,s board of directors,since 2000, ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... Administration (FDA) review, the Company is initiating ... administration of REOLYSIN(R) in,combination with paclitaxel and ... (NSCLC) with K-RAS or EGFR-activated tumours. The ...
Cached Biology Technology:NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 2Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 3Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer 4Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 4
(Date:8/22/2014)... 2014 Research ... the addition of the  "Biometrics Market ... their offering.       (Logo: ... technology that helps in the identification ... or behavioral features. It involves verification ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... La Jolla, CA Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats ... that cause 70 percent of all cervical cancer. ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 ... Ph.D. and Thomas Broker, Ph.D., who presented the ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... been identified in sediment-laden marine environments, conditions previously believed to ... that Middle Reef part of Australia,s iconic Great Barrier ... in areas with lower levels of sediment stress. Led ... team of scientists is published today (1 August 2012) in ...
... from the Wildlife Conservation Society (WCS) and the National Research ... called an imperial cormorant with a small camera, then watched ... in 40 seconds, feeding on the ocean floor for 80 ... to the surface 40 seconds later. This is the ...
... appendages that plague many people in the winter and an ... for singles and couples alike. In a new study, scientists ... Nationwide Children,s Hospital have identified a biological mechanism that may ... of molecules and receptors on smooth muscle cells that line ...
Cached Biology News:Coral reef thriving in sediment-laden waters 2Are cold feet plaguing your relationship? 2Are cold feet plaguing your relationship? 3
... imaging system from Molecular Devices is ... for automated acquisition and analysis of ... ImageXpressULTRA is powered by MetaXpress, ... acquisition, image storage and analysis. MetaXpress ...
... Bioimager is an automated, confocal, real-time, single ... has been integrated into a single, compact ... to provide high-resolution, automated confocal imaging with ... better cell-based assays. The system allows the ...
... uses a simplified procedure and streamlines the ... kit is based on the three step ... sodium bisulfite where cytosine is converted into ... in-column desulphonation reaction eliminates several precipitation steps ...
... The DIGIVIEW line of digital x-ray detectors ... imaging device complete with 12 to 16 ... consists of a photodiode array sensor with ... models are available in low x-ray energies ...
Biology Products: